<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ESTRACE- estradiolÂ creamÂ </strong><br>Warner Chilcott (US), LLC<br></p></div>
<h1>ESTRACE<span class="Sup">Â®</span> CREAM <br> (estradiol vaginal cream, USP, 0.01%)<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_66899794-dd3a-4b24-a615-c1909082fae2"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER</span></h1>
<p class="First">Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of â€œnaturalâ€? estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses (see <span class="Bold"><a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a>, <a href="#i4i_section_id_5e043faf-7000-423e-b2b5-e3b114405a2b">Malignant neoplasms</a>, <span class="Italics"><a href="#i4i_section_id_dfaedd9a-a9d3-4cfa-8c37-bafb3fef7975">Endometrial cancer</a></span></span>).</p>
<p><span class="Bold">CARDIOVASCULAR AND OTHER RISKS</span></p>
<p>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease (see <span class="Bold"><a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a>, <a href="#i4i_section_id_e78fa585-8c43-476b-bb9b-b8a9442e0d8b"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span>).</p>
<p>The Womenâ€™s Health Initiative (WHI) study reported increased risks of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60">Clinical Studies</a></span>).</p>
<p>The Womenâ€™s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen-alone therapy (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60">Clinical Studies</a></span>).</p>
<p>Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc05a33f-92dd-4053-916f-b9a3f9f7df0c"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_4f50c3e1-7587-44d8-8be1-89e7bca9e223"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each gram of ESTRACE<span class="Sup">Â®</span> (estradiol vaginal cream, USP, 0.01%) contains 0.1 mg estradiol in a nonliquefying base containing purified water, propylene glycol, stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208 (4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and <span class="Italics">tertiary</span>-butylhydroquinone. Estradiol is chemically described as estra-1,3,5(10)-triene-3,17Î²-diol. It has an empirical formula of C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2 </span>and molecular weight of 272.37. The structural formula is: </p>
<p><img alt="Estradiol structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e&amp;name=cd3b5d4b-6a3c-4b13-a0b1-5ac63e0d8cb4-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level.  </p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. </p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_4badc235-50da-47c3-b3c2-baabbb049bc4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad25d88e-7097-4e40-bb0b-7b2c9c1c9955"></a><a name="section-3.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Absorption</span></span></h3>
<p class="First">Estrogen drug products are absorbed through the skin, mucous membranes, and the gastrointestinal tract after release from the drug formulation.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3206f52a-45a1-46df-b020-1449c2c82cf3"></a><a name="section-3.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Distribution</span></span></h3>
<p class="First">The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_143bb42e-021e-45c9-a990-463b7be0c43a"></a><a name="section-3.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Metabolism</span></span></h3>
<p class="First">Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions.  These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite.  Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5782292b-b36c-40ce-bf9a-bedc90666f1f"></a><a name="section-3.1.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Excretion</span></span></h3>
<p class="First">Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e9502e1-2de1-4a51-97b4-dae54fdba57c"></a><a name="section-3.1.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Special Populations</span></span></h3>
<p class="First">No pharmacokinetic studies were conducted in special populations, including patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_6532f180-6400-490b-934f-c292f4aad8b6"></a><a name="section-3.1.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Drug Interactions</span></span></h3>
<p class="First">In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. Johnâ€™s Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and mayÂ  result in side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60"></a><a name="section-3.2"></a><p></p>
<h2>Clinical Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27a9cc3f-6816-4290-93e2-ec1baa0b6feb"></a><a name="section-3.2.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Womenâ€™s Health Initiative Studies</span></span></h3>
<p class="First">The Womenâ€™s Health Initiative (WHI) enrolled a total of 27,000 predominantly healthy postmenopausal women to assess the risks and benefits of either the use of oral 0.625 mg conjugated estrogens (CE) per day alone or the use of oral 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate (MPA) per day compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome studied. A â€œglobal indexâ€? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. The study did not evaluate the effects of CE or CE/MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>. </p>
<p>The CE/MPA substudy was stopped early because, according to the predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the â€œglobal indexâ€?. Results of the CE/MPA substudy, which included 16,608 women (average age of 63Â years, range 50 to 79; 83.9 percent White, 6.5 percent Black, 5.5 percent Hispanic), after an average follow-up of 5.2Â years are presented in <a href="#id_71e76793-1b70-411a-acde-b0b326f09bfb">Table 1</a> below:</p>
<a name="id_71e76793-1b70-411a-acde-b0b326f09bfb"></a><table border="single" width="724">
<caption><span>Table 1.  RELATIVE AND ABSOLUTE RISK SEEN IN THE CE/MPA SUBSTUDY OF WHI<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="34.1%">
<col width="29.6%">
<col width="17.4%">
<col width="18.9%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>adapted from JAMA, 2002; 288:321-333</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>a subset of the events was combined in a â€œglobal indexâ€?, defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>,  or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>nominalÂ confidenceÂ intervalsÂ unadjustedÂ forÂ multipleÂ looksÂ andÂ multipleÂ comparisons</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd>includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">Â¶</a></dt>
<dd>not included in Global Index </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">Event<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">
<p class="First">Relative Risk <br>CE/MPA versus placebo<br> at 5.2 Years</p>(95 percent CI<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo<br>n = 8102</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">CE/MPA</p>n = 8506</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">Absolute Risk per 10,000 Women-years</td></tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">CHD events</td>
<td class="Rrule" align="left" valign="top">1.29 (1.02  to 1.63)</td>
<td class="Rrule" align="left" valign="top">30</td>
<td class="Rrule" align="left" valign="top">37</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Italics"> Â Â Â Â Â Non-fatal MI</span></td>
<td class="Rrule" align="left" valign="top"><span class="Italics">1.32 (1.02  to 1.72)</span></td>
<td class="Rrule" align="left" valign="top"><span class="Italics">23</span></td>
<td class="Rrule" align="left" valign="top"><span class="Italics">30</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics"> Â Â Â Â Â CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Italics">1.18 (0.70  to 1.97)</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Italics">6</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Italics">7</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive breast cancer<a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.26 (1.00  to 1.59)</td>
<td class="Botrule Rrule" align="left" valign="top">30</td>
<td class="Botrule Rrule" align="left" valign="top">38</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td class="Botrule Rrule" align="left" valign="top">1.41 (1.07  to 1.85)</td>
<td class="Botrule Rrule" align="left" valign="top">21</td>
<td class="Botrule Rrule" align="left" valign="top">29</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td class="Botrule Rrule" align="left" valign="top">2.13 (1.39  to 3.25)</td>
<td class="Botrule Rrule" align="left" valign="top">8</td>
<td class="Botrule Rrule" align="left" valign="top">16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Colorectal cancer</td>
<td class="Botrule Rrule" align="left" valign="top">0.63 (0.43  to 0.92)</td>
<td class="Botrule Rrule" align="left" valign="top">16</td>
<td class="Botrule Rrule" align="left" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Endometrial cancer</td>
<td class="Botrule Rrule" align="left" valign="top">0.83 (0.47  to 1.47)</td>
<td class="Botrule Rrule" align="left" valign="top">6</td>
<td class="Botrule Rrule" align="left" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></td>
<td class="Botrule Rrule" align="left" valign="top">0.66 (0.45  to 0.98)</td>
<td class="Botrule Rrule" align="left" valign="top">15</td>
<td class="Botrule Rrule" align="left" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to causes other than the events above</td>
<td class="Botrule Rrule" align="left" valign="top">0.92 (0.74  to 1.14)</td>
<td class="Botrule Rrule" align="left" valign="top">40</td>
<td class="Botrule Rrule" align="left" valign="top">37</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Global Index <a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.15 (1.03  to 1.28)</td>
<td class="Botrule Rrule" align="left" valign="top">151</td>
<td class="Botrule Rrule" align="left" valign="top">170</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span> <a name="footnote-reference-5" href="#footnote-5" class="Sup">Â¶</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">2.07 (1.49  to 2.87)</td>
<td class="Botrule Rrule" align="left" valign="top">13</td>
<td class="Botrule Rrule" align="left" valign="top">26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span> <a href="#footnote-5" class="Sup">Â¶</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">0.66 (0.44  to 0.98)</td>
<td class="Botrule Rrule" align="left" valign="top">15</td>
<td class="Botrule Rrule" align="left" valign="top">9</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Other <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span> <a href="#footnote-5" class="Sup">Â¶</a>
</td>
<td class="Rrule" align="left" valign="top">0.77 (0.69  to 0.86)</td>
<td class="Rrule" align="left" valign="top">170</td>
<td class="Botrule Rrule" align="left" valign="top">131</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the "global indexâ€?, the absolute excess risks per 10,000 women-years in the group treated with CE/MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 8 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the â€œglobal indexâ€? was 19 per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality (see <span class="Bold"><a href="#id_66899794-dd3a-4b24-a615-c1909082fae2">BOXED WARNINGS</a>, <a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a>, </span>and<span class="Bold"><a href="#i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240"> PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94164715-8deb-4ba9-93a4-733e1a508c52"></a><a name="section-3.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Womenâ€™s Health Initiative Memory Study</span></span></h3>
<p class="First">The Womenâ€™s Health Initiative Memory Study (WHIMS), a substudy of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were age 65 to 69 years, 35 percent were 70 to 74 years, and 18 percent were 75 years of age and older) to evaluate the effects of CE/MPA (0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the estrogen/progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95 percent CI, 1.21 to 3.48) compared to placebo. Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women (see <span class="Bold"><a href="#id_66899794-dd3a-4b24-a615-c1909082fae2">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a></span>, <span class="Bold"><a href="#i4i_section_id_b54031c1-8ec0-4f69-87ec-bfb9d7ed104f"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2a8ad085-aca1-4852-b540-9467d30067e1"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ESTRACE (estradiol vaginal cream, USP, 0.01%) is indicated in the treatment of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7183ff55-5ef0-4885-88df-61938ead8723"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ESTRACE (estradiol vaginal cream, USP, 0.01%) should not be used in women with any of the following conditions:</p>
<ol>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Known, suspected, or history of cancer of the breast. </li>
<li>Known or suspected estrogen-dependent neoplasia.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or history of these conditions.</li>
<li>Active or recent (for example, within the past year) arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</li>
<li>Liver dysfunction or disease.</li>
<li>ESTRACE (estradiol vaginal cream, USP, 0.01%) should not be used in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to its ingredients.</li>
<li>Known or suspected pregnancy. There is no indication for ESTRACE (estradiol vaginal cream, USP, 0.01%) in pregnancy. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy (see <span class="Bold"><a href="#i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240">PRECAUTIONS</a></span>).</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See<span class="Bold">Â <a href="#id_66899794-dd3a-4b24-a615-c1909082fae2">BOXED WARNINGS</a></span>.</p>
<p>Systemic absorption may occur with the use of ESTRACE (estradiol vaginal cream, USP, 0.01%). The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e78fa585-8c43-476b-bb9b-b8a9442e0d8b"></a><a name="section-6.1"></a><p></p>
<h2>1.Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></h2>
<p class="First">Estrogen and estrogen/progestin therapy has been associated with an increased risk of cardiovascular events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, as well as <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (<span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> or VTE). Should any of these occur or be suspected, estrogens should be discontinued immediately.  </p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (for example, personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91109b3b-6d0d-4a27-8424-ada3cfbf0899"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">a.Â Â Â Â Â <span class="Italics">Coronary heart disease and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></span></span></h3>
<p class="First">In the Womenâ€™s Health Initiative (WHI) study, an increase in the number of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60">Clinical Studies</a></span>).</p>
<p>In the CE/MPA substudy of WHI, an increased risk of coronary heart disease (CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was observed in women receiving CE/MPA compared to women receiving placebo (37 versus 30 per 10,000 women-years). The increase in risk was observed in year one and persisted.  </p>
<p>In the same substudy of WHI, an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed in women receiving CE/MPA compared to women receiving placebo (29 versus 21 per 10,000 women-years). The increase in risk was observed after the first year and persisted.  </p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 66.7Â years) a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS) treatment with CE/MPA (0.625 mg/2.5 mg per day) demonstrated no cardiovascular benefit. During an average follow-up of 4.1Â years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE/MPA-treated group than in the placebo group in yearÂ 1, but not during the subsequent years. Two thousand three hundred and twenty one women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7Â years, for a total of 6.8Â years overall. Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.  </p>
<p>Large doses of estrogen (5Â mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0231f7f7-3cef-4bc5-937e-c4123d65f3cb"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">b.Â Â Â Â Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> (VTE)</span></span></h3>
<p class="First">In the Womenâ€™s Health Initiative (WHI) study, an increase in VTE has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60">Clinical Studies</a></span>).  </p>
<p>In the CE/MPA substudy of WHI, a 2-fold greater rate of VTE, including deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, was observed in women receiving CE/MPA compared to women receiving placebo. The rate of VTE was 34 per 10,000 women-years in the CE/MPA group compared to 16 per 10,000 women-years in the placebo group.  The increase in VTE risk was observed during the first year and persisted.  </p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e043faf-7000-423e-b2b5-e3b114405a2b"></a><a name="section-6.2"></a><p></p>
<h2>2.Â Â Â Â Â Malignant neoplasms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfaedd9a-a9d3-4cfa-8c37-bafb3fef7975"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold">a.Â Â Â Â Â <span class="Italics">Endometrial cancer</span></span></h3>
<p class="First">The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than one year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for five to ten years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women taking estrogen/progestin combinations is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. </p>
<p><span class="Bold">b.Â Â Â Â Â <span class="Italics">Breast cancer</span></span></p>
<p>The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer. The most important randomized clinical trial providing information about this issue is the Womenâ€™s Health Initiative (WHI) substudy of CE/MPA (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721">CLINICAL PHARMACOLOGY</a></span>, <span class="Bold"><a href="#i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60">Clinical Studies</a></span>). The results from observational studies are generally consistent with those of the WHI clinical trial and report no significant variation in the risk of breast cancer among different estrogens or progestins, doses, or routes of administration.</p>
<p>The CE/MPA substudy of WHI reported an increased risk of breast cancer in women who took CE/MPA for a mean follow-up of 5.6 years. Observational studies have also reported an increased risk for estrogen/progestin combination therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. In the WHI trial and from observational studies, the excess risk increased with duration of use. From observational studies, the risk appeared to return to baseline in about five years after stopping treatment. In addition, observational studies suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen/progestin combination therapy as compared to estrogen-alone therapy. </p>
<p>In the CE/MPA substudy, 26 percent of the women reported prior use of estrogen-alone and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 5.6 years during the clinical trial, the overall relative risk of invasive breast cancer was 1.24 (95 percent confidence interval 1.01 to 1.54), and the overall absolute risk was 41 versus 33 cases per 10,000 women-years for CE/MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE/MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE/MPA compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups. </p>
<p>The use of estrogen-plus-progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b54031c1-8ec0-4f69-87ec-bfb9d7ed104f"></a><a name="section-6.3"></a><p></p>
<h2>3.Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the Womenâ€™s Health Initiative Memory Study (WHIMS), 4,532 generally healthy postmenopausal women 65 years of age and older were studied, of whom 35 percent were 70 to 74 years of age and 18 percent were 75 or older. After an average follow-up of 4 years, 40 women being treated with CE/MPA (1.8 percent, n = 2,229) and 21 women in the placebo group (0.9 percent, n = 2,303) received diagnoses of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk for CE/MPA versus placebo was 2.05 (95 percent confidence interval 1.21 to 3.48), and was similar for women with and without histories of menopausal hormone use before WHIMS. The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA versus placebo was 45 versus 22 cases per 10,000 women-years, and the absolute excess risk for CE/MPA was 23 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f1e6d835-d4b3-4648-8634-5d42ec1c0721">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_45b0b143-0690-46e0-a0bb-18d29f575d60">Clinical Studies</a></span> and <a href="#i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240"></a><span class="Bold"><a href="#i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240">PRECAUTIONS</a>, <a href="#i4i_geriatric_use_id_1e1b869c-d661-4414-8564-0f2f0edc947d">Geriatric Use</a></span>).</p>
<p>It is unknown whether these findings apply to estrogen-alone therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd2b6aa8-b7f7-44fc-b4cc-67717a9441b8"></a><a name="section-6.4"></a><p></p>
<h2>4.Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2fe634a-7f04-42c9-ac41-835072b1ebfa"></a><a name="section-6.5"></a><p></p>
<h2>5.Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f90404fc-0722-415d-8faf-1f3d52d5c6e5"></a><a name="section-6.6"></a><p></p>
<h2>6.Â Â Â Â Â Visual abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens.  Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_8da21435-1046-4e04-a4e0-ae12b92505ad"></a><a name="section-7.1"></a><p></p>
<h2>A.Â Â Â Â Â GENERAL</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_719e3671-3669-4528-b63c-f5383ec9d6b3"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Bold">1.Â Â Â Â Â <span class="Italics">Addition of a progestin when a woman has not had a hysterectomy</span></span></h3>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone.  <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include a possible increased risk of breast cancer. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28a09a0c-af3e-45cb-9e57-015b78ca4865"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="Bold">2.Â Â Â Â Â <span class="Italics">Elevated blood pressure</span></span></h3>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.  Blood pressure should be monitored at regular intervals with estrogen use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49043800-a9a4-4f62-9167-e0b555e5990d"></a><a name="section-7.1.3"></a><p></p>
<h3><span class="Bold">3.Â Â Â Â Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></span></span></h3>
<p class="First">In patients with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and other complications. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c878c58-5c2a-419c-b798-dec4e4b057d6"></a><a name="section-7.1.4"></a><p></p>
<h3><span class="Bold">4.Â Â Â Â Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired liver function</span> and past history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span></span></span></h3>
<p class="First">Estrogens may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb886723-c395-4cf1-beac-d029eafed8df"></a><a name="section-7.1.5"></a><p></p>
<h3><span class="Bold">5.Â Â Â Â Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></span></span></h3>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.  Patients with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy.  These patients should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb9fd20f-75ce-49a4-902e-1fe46760722e"></a><a name="section-7.1.6"></a><p></p>
<h3><span class="Bold">6.Â Â Â Â Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></span></span></h3>
<p class="First">Because estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, patients with conditions that might be influenced by this factor, such as a cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f2d4a69-fae5-4dab-8599-a0b8cfaa8407"></a><a name="section-7.1.7"></a><p></p>
<h3><span class="Bold">7.Â Â Â Â Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></span></span></h3>
<p class="First">Estrogens should be used with caution in individuals with severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d9849f5-0645-4780-80af-44e62e2524c9"></a><a name="section-7.1.8"></a><p></p>
<h3><span class="Bold">8.Â Â Â Â Â <span class="Italics">Ovarian cancer</span></span></h3>
<p class="First">The CE/MPA substudy of WHI reported that estrogen-plus-progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE/MPA versus placebo was 1.58 (95 percent confidence interval 0.77 to 3.24) but was not statistically significant. The absolute risk for CE/MPA versus placebo was 4.2 versus 2.7 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen alone, in particular for ten or more years, has been associated with an increased risk of ovarian cancer. Other epidemiologic studies have not found these associations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_83c43749-fa53-46cc-a513-790ff048c550"></a><a name="section-7.1.9"></a><p></p>
<h3><span class="Bold">9.Â Â Â Â <span class="Italics">Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span></span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens. A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For patients known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35e49ca5-eea8-424e-ab7e-52503b20d882"></a><a name="section-7.1.10"></a><p></p>
<h3><span class="Bold">10.Â Â Â Â <span class="Italics">Exacerbation of other conditions</span></span></h3>
<p class="First">Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_4bec5cb2-f8a7-4b6a-9ab0-20ae344a4f0b"></a><a name="section-7.2"></a><p></p>
<h2>B.Â Â Â Â Â PATIENT INFORMATION</h2>
<p class="First">Physicians are advised to discuss the <a href="#i4i_patient_package_insert_id_65286f71-0f8e-4394-8680-bfb163f3a024">PATIENT INFORMATION</a> leaflet with patients for whom they prescribe ESTRACE (estradiol vaginal cream, USP, 0.01%).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_4dc2c124-c53b-4141-a427-1bd4085a920d"></a><a name="section-7.3"></a><p></p>
<h2>C.Â Â Â Â Â LABORATORY TESTS</h2>
<p class="First">Estrogen administration should be initiated at the lowest dose approved for the indication and then guided by clinical response rather than by serum hormone levels (for example, estradiol, FSH).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_0c190303-a5e3-4ac7-a014-2157d3ab161b"></a><a name="section-7.4"></a><p></p>
<h2>D.Â Â Â Â Â DRUG/LABORATORY TEST INTERACTIONS</h2>
<ol>
<li>Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity. </li>
<li>Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> levels (by column or by radioimmunoassay) or T<span class="Sub">3</span> levels by radioimmunoassay. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. </li>
<li>Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>). </li>
<li>Increased plasma HDL and HDL<span class="Sub">2</span> subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglycerides levels. </li>
<li>Impaired glucose tolerance. </li>
<li>Reduced response to metyrapone test. </li>
<li>Reduced serum folate concentration. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a67a4ee6-e80c-4e3e-8f94-ba29631bb907"></a><a name="section-7.5"></a><p></p>
<h2>E.Â Â Â Â Â CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY</h2>
<p class="First">Long-term continuous administration of estrogen, with and without progestin, in women with and without a uterus, has shown an increased risk of endometrial cancer, breast cancer, and ovarian cancer (see <span class="Bold"><a href="#id_66899794-dd3a-4b24-a615-c1909082fae2">BOXED WARNINGS</a>, <a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a>Â </span>and <span class="Bold"><a href="#i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240">PRECAUTIONS</a></span>).</p>
<p>Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2edd5a7c-89b4-405f-a2a9-5176601bb060"></a><a name="section-7.6"></a><p></p>
<h2>F.Â Â Â Â Â PREGNANCY</h2>
<p class="First">ESTRACE (estradiol vaginal cream, USP, 0.01%) should not be used during pregnancy (see <span class="Bold"><a href="#i4i_contraindications_id_7183ff55-5ef0-4885-88df-61938ead8723">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_bfaf46d0-34d6-4556-b7f7-825eb8b1d2c6"></a><a name="section-7.7"></a><p></p>
<h2>G.Â Â Â Â Â NURSING MOTHERS</h2>
<p class="First">Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving this drug. Caution should be exercised when ESTRACE (estradiol vaginal cream, USP, 0.01%) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_633de64b-ddfa-4d3f-b27b-03fab76027fb"></a><a name="section-7.8"></a><p></p>
<h2>H.Â Â Â Â Â PEDIATRIC USE</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Large and repeated doses of estrogen over an extended period of time have been shown to accelerate epiphyseal closure, resulting in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children. In patients in whom bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended. </p>
<p>Estrogen treatment of prepubertal children also induces premature breast development and vaginal cornification, and may potentially induce <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> in girls. In boys, estrogen treatment may modify the normal pubertal process. All other physiological and adverse reactions shown to be associated with estrogen treatment of adults could potentially occur in the pediatric population, including thromboembolic disorders and growth stimulation of certain tumors. Therefore, estrogens should only be administered to pediatric patients when clearly indicated and the lowest effective dose should always be utilized.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_1e1b869c-d661-4414-8564-0f2f0edc947d"></a><a name="section-7.9"></a><p></p>
<h2>I.Â Â Â Â Â GERIATRIC USE</h2>
<p class="First">In the Womenâ€™s Health Initiative Memory Study, including 4,532 women 65 years of age and older, followed for an average of 4 years, 82 percent (n = 3,729) were 65 to 74 while 18 percent (n = 803) were 75 and over. Most women (80 percent) had no prior hormone therapy use. Women treated with conjugated estrogens-plus-medroxyprogesterone acetate were reported to have a two-fold increase in the risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Alzheimerâ€™s disease was the most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the conjugated estrogens-plus-medroxyprogesterone acetate group and the placebo group. Ninety percent of the cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in the 54 percent of women that were older than 70 (see <span class="Bold"><a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a>, <a href="#i4i_section_id_b54031c1-8ec0-4f69-87ec-bfb9d7ed104f"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>).</p>
<p>There have not been sufficient numbers of geriatric patients involved in studies utilizing ESTRACE (estradiol vaginal cream, USP, 0.01%) to determine whether those over 65 years of age differ from younger subjects in their response to ESTRACE (estradiol vaginal cream, USP, 0.01%). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_55aa3f2e-cb18-4282-b8bf-8136519a347a"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">See <span class="Bold"><a href="#id_66899794-dd3a-4b24-a615-c1909082fae2">BOXED WARNINGS</a>, <a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a></span> and <span class="Bold"><a href="#i4i_precautions_id_f17fd9a2-8d61-4771-a920-8f142b4f4240">PRECAUTIONS</a></span>.</p>
<p>Systemic absorption may occur with the use of ESTRACE (estradiol vaginal cream, USP, 0.01%). The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account.</p>
<p>The following additional adverse reactions have been reported with estrogen and/or progestin therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88e972c2-a5bb-4366-b25a-65b1fbb16f94"></a><a name="section-8.1"></a><p></p>
<h2>1.Â Â Â Â Â Genitourinary system</h2>
<p class="First">Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, increase in size of uterine leiomyomata; <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>; <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> of <span class="product-label-link" type="condition" conceptid="4320923" conceptname="Vulvovaginal discomfort">vulvovaginal discomfort</span> including burning and irritation; <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span>; ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d85d7ec-6e64-4a74-bf17-c0486ba2579c"></a><a name="section-8.2"></a><p></p>
<h2>2.Â Â Â Â Â Breasts</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d91b2031-b7cb-4b37-9a00-3bdf7da6d6c3"></a><a name="section-8.3"></a><p></p>
<h2>3.Â Â Â Â Â Cardiovascular</h2>
<p class="First">Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_294ba545-4630-4035-be36-302c69d79621"></a><a name="section-8.4"></a><p></p>
<h2>4.Â Â Â Â Â Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, enlargement of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f4500e8d-895b-44ca-9bba-958291dff291"></a><a name="section-8.5"></a><p></p>
<h2>5.Â Â Â Â Â Skin</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span>, that may persist when drug is discontinued; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5bf64470-084f-4d75-90d2-0fa9cba483be"></a><a name="section-8.6"></a><p></p>
<h2>6.Â Â Â Â Â Eyes</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, intolerance to contact lenses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c1e0ba9-d24b-45b2-bfa3-d81502ad98ec"></a><a name="section-8.7"></a><p></p>
<h2>7.Â Â Â Â Â Central nervous system</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_585c158f-57ff-407c-a7c2-8d56f7698294"></a><a name="section-8.8"></a><p></p>
<h2>8.Â Â Â Â Â Miscellaneous</h2>
<p class="First">Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; changes in libido; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, anaphylactoid/anaplylactic reactions; <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_40df7140-47c1-48da-9e4c-b07d45672357"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing drug products by young children. Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_86f7a597-557f-4f48-aa97-b44154b9c6cb"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Use of ESTRACE (estradiol vaginal cream, USP, 0.01%), alone or in combination with a progestin, should be limited to the shortest duration consistent with treatment goals and risks for the individual woman. Patients should reevaluate periodically as clinically appropriate (for example, 3-month to 6-month intervals) to determine if treatment is still necessary (see <span class="Bold"><a href="#id_66899794-dd3a-4b24-a615-c1909082fae2">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_91acbe2b-52cc-4de7-b544-29d21a3a5f6f">WARNINGS</a></span>). For treatment of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. </p>
<p>Usual Dosage: The usual dosage range is 2 to 4 g (marked on the applicator) daily for one or two weeks, then gradually reduced to one half initial dosage for a similar period. A maintenance dosage of 1 g, one to three times a week, may be used after restoration of the vaginal mucosa has been achieved. </p>
<p><span class="Bold">NOTE: The number of doses per tube will vary with dosage requirements and patient handling. </span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_be39ba41-7f8a-44ce-828b-8550a96cfe64"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">ESTRACE<span class="Sup">Â®</span> (estradiol vaginal cream, USP, 0.01%). </span></p>
<p><span class="Bold">N</span> 0430-3754-14: Tube containing 1 Â½ oz (42.5 g) with a calibrated plastic applicator for delivery of 1, 2, 3, or 4 g. </p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_7b33c08b-a59a-4193-b812-f105464999d5"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Store at room temperature. Protect from temperatures in excess of 40Â° C (104Â° F). </span></p>
<p><span class="Bold">Keep ESTRACE Vaginal Cream out of the reach of children.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_65286f71-0f8e-4394-8680-bfb163f3a024"></a><a name="section-12"></a><p></p>
<h1>INFORMATION FOR THE PATIENT</h1>
<p class="First"><span class="Bold">(Updated December 2011)</span></p>
<p><span class="Bold">NOTE: The number of doses per tube will vary with dosage requirements and patient handling. </span>Â </p>
<p>Read this PATIENT INFORMATION before you start using ESTRACE<span class="Sup">Â®</span> Vaginal Cream and read what you get each time you refill ESTRACE Vaginal Cream. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.Â </p>
<div class="Warning">
<a name="id_7b874e55-d3dd-407b-afe5-6180da961e3f"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT ESTRACE VAGINAL CREAM (AN ESTROGEN HORMONE)?</span><br><br></p>
<ul><li>Estrogens increase the chances of getting cancer of the uterus.<br>
</li></ul>
<p>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are taking estrogens. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.<br>Â  </p>
<ul><li>Do not use estrogens with or without progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.<br>
</li></ul>
<p>Using estrogens with or without progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. You and your healthcare provider should talk regularly about whether you still need treatment with ESTRACE Vaginal Cream.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_3e76c523-a772-49f6-a587-2048d77d65e3"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">What isÂ ESTRACEÂ Vaginal Cream?Â </span></p>
<p>ESTRACE Vaginal Cream is a medicine that contains estrogen hormones.</p>
<p><span class="Bold">What is ESTRACE Vaginal Cream used for?</span>Â </p>
<p>ESTRACE Vaginal Cream is used to:Â <br><br></p>
<ul><li>treat moderate to severe dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and burning in and around the vagina due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. You and your healthcare provider should talk regularly about whether you still need treatment with ESTRACE Vaginal Cream to control these problems. </li></ul>
<p><span class="Bold">Who should not use ESTRACE Vaginal Cream?</span>Â </p>
<p>Do not start using ESTRACE Vaginal Cream if you:Â <br><br></p>
<ul><li><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></li></ul>
<ul><li><span class="Bold">currently have or have had certain cancers</span></li></ul>
<p>Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should use ESTRACE Vaginal Cream.<br><br></p>
<ul><li><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year</span></li></ul>
<ul><li><span class="Bold">currently have or have had blood clots</span></li></ul>
<ul><li><span class="Bold">currently have or have had liver problems</span></li></ul>
<ul><li><span class="Bold">are allergic to ESTRACE Vaginal Cream or any of its ingredients</span></li></ul>
<p>See the end of this leaflet for a list of ingredients in ESTRACE Vaginal CreamÂ <br><br></p>
<ul><li><span class="Bold">think you may be pregnant</span></li></ul>
<p>Tell your healthcare provider:Â <br><br></p>
<ul><li><span class="Bold">if you are breastfeeding</span></li></ul>
<p>The hormone in ESTRACE Vaginal Cream can pass into your milk.Â <br><br></p>
<ul><li><span class="Bold">about all of your medical problems</span></li></ul>
<p>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.Â <br><br></p>
<ul><li><span class="Bold">about all the medicines you take</span></li></ul>
<p>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how ESTRACE Vaginal Cream works.  ESTRACE Vaginal Cream may also affect how your other medicines work.Â <br><br></p>
<ul><li><span class="Bold">if you are going to have surgery or will be on bed rest.</span></li></ul>
<p>You may need to stop taking estrogens.Â </p>
<p><span class="Bold">How should I use ESTRACE Vaginal Cream?</span>Â </p>
<ol>
<li>Remove cap from tube. (There is no seal on tube)</li>
<li>Do not separate plunger from applicator.</li>
<li>Screw threaded end of applicator onto the opened tube until secure.</li>
<li>Position upright in order to view the calibrated gram amounts.</li>
<li>Gently squeeze tube from the bottom to expel the prescribed amount of ESTRACE Vaginal Cream into the applicator. As cream is squeezed out, plunger will rise to indicate amount of grams.</li>
<li>Unscrew applicator from tube.</li>
<li>Replace cap onto tube.</li>
<li>Lie on back with knees drawn up. To deliver medication, gently insert applicator deeply into the vagina and press plunger downward to its original position.</li>
<li>To cleanse applicator: Pull plunger to remove it from barrel. Wash with mild soap and warm water. DO NOT <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">BOIL</span> OR USE HOT WATER.</li>
</ol>
<p>ESTRACE Vaginal Cream should be used at the lowest dose possible for your treatment only as long as needed. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with ESTRACE Vaginal Cream. <br>Â </p>
<p><span class="Bold">What are the possible side effects of ESTRACE Vaginal Cream?</span>Â </p>
<p>Although ESTRACE Vaginal Cream is only used in and around the vagina, the risks associated with oral estrogens should be taken into account.</p>
<p><span class="Bold">Less common but serious side effects include:</span>Â </p>
<ul>
<li>Breast cancer</li>
<li>Cancer of the uterus</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span></li>
<li>Blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li>Ovarian cancer</li>
</ul>
<p><span class="Bold">These are some of the warning signs of serious side effects:</span>Â </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span></li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness</li>
<li>Changes in speech</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs</li>
<li>Changes in vision</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
</ul>
<p>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.</p>
<p><span class="Bold">Common side effects include:</span>Â </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span></li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span></li>
<li>Vaginal burning, irritation, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
</ul>
<p><span class="Bold">Other side effects include:</span></p>
<ul>
<li>High blood pressure</li>
<li>Liver problems</li>
<li>High blood sugar</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li>Enlargement of benign tumors of the uterus (â€œfibroidsâ€?)</li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></li>
</ul>
<p>These are not all the possible side effects of ESTRACE Vaginal Cream. For more information, ask your healthcare provider or pharmacist.Â </p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with ESTRACE Vaginal Cream?</span>Â </p>
<p>Talk with your healthcare provider regularly about whether you should continue using ESTRACE Vaginal Cream. See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while using ESTRACE Vaginal Cream. Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often. If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease.Â </p>
<p><span class="Bold">General information about safe and effective use of ESTRACE Vaginal Cream</span>Â </p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use ESTRACE Vaginal Cream for conditions for which it was not prescribed. Do not give ESTRACE Vaginal Cream to other people, even if they have the same symptoms you have. It may harm them.Â </p>
<p><span class="Bold">Keep ESTRACE Vaginal Cream out of the reach of children.</span>Â </p>
<p>This leaflet provides a summary of the most important information about ESTRACE Vaginal Cream. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about ESTRACE Vaginal Cream that is written for health professionals. You can get more information by calling the toll free number 1-800-521-8813.Â </p>
<p><span class="Bold">What are the ingredients in ESTRACE Vaginal Cream?</span>Â </p>
<p>Each gram of ESTRACE Vaginal Cream contains 0.1 mg estradiol in a nonliquefying base containing purified water, propylene glycol, stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208 (4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and <span class="Italics">tertiary</span>-butylhydroquinone.Â </p>
<p>Manufactured by: <br>Contract Pharmaceuticals Limited <br>Mississauga, Ontario, Canada L5N 6L6<br>for Warner Chilcott (US), LLC <br>Rockaway, NJ 07866</p>
<p>Marketed by: <br>Warner Chilcott (US), LLC<br>Rockaway, NJ 07866<br>1-800-521-8813</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Warner Chilcott at 1-800-521-8813 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
<div class="Figure"><img alt="Warner Chilcott (US) logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e&amp;name=cd3b5d4b-6a3c-4b13-a0b1-5ac63e0d8cb4-02.jpg"></div>
<p>3754G170Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Revised: December 2011</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7743e42e-ddec-4de4-8b73-46b701e5dea0"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - CARTON LABEL - 1Â½Â OZÂ (42.5 g)</h1>
<p class="First">Â </p>
<div class="Figure"><img alt="ESTRACE Cream (estradiol vaginal cream, USP, 0.01%) carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e&amp;name=cd3b5d4b-6a3c-4b13-a0b1-5ac63e0d8cb4-03.jpg"></div>
<p><span class="Bold">N</span> 0430-3754-14</p>
<p>Each gram contains 0.1 mg estradiol in a nonliquefying base.</p>
<p><span class="Bold">Usual Dosage:</span> See enclosed Package Insert for Full Prescribing Information.</p>
<p><span class="Bold">CAUTION: </span>Keep this and all medications out of the reach of children.</p>
<p><span class="Bold">ESTRACE<span class="Sup">Â®</span>Â CREAM</span><br>(estradiol vaginal cream, USP, 0.01%)</p>
<p><span class="Bold">UNSCENTEDÂ </span></p>
<p><span class="Bold">RxÂ only</span></p>
<p><span class="Bold">NETÂ WTÂ 1Â½Â OZÂ (42.5Â G)Â TUBE</span></p>
<p><span class="Bold">StoreÂ atÂ roomÂ temperature.Â <br>Protect from temperatures in excess of 40Â° C (104Â° F).Â <br>DispenseÂ WithÂ Insert.</span></p>
<p><span class="Bold">CALIBRATEDÂ APPLICATORÂ ENCLOSED</span></p>
<p>ThisÂ productÂ alsoÂ containsÂ purified water, propylene glycol, stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose, sodium lauryl sulfate, methylparaben, edetate disodium and <span class="Italics">t</span>-butylhydroquinone.</p>
<p><span class="Bold">ReadÂ AccompanyingÂ InformationÂ ForÂ TheÂ Patient</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bcc8241a-2821-46e3-aa10-69505b3afc50"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY LABEL - TUBE LABEL - 1Â½Â OZÂ (42.5 g)</h1>
<p class="First">Â </p>
<div class="Figure"><img alt="ESTRACE Cream (estradiol vaginal cream, USP, 0.01%) tube label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e&amp;name=cd3b5d4b-6a3c-4b13-a0b1-5ac63e0d8cb4-04.jpg"></div>
<p><span class="Bold">N</span> 0430-3754-14Â </p>
<p><span class="Bold">ESTRACE<span class="Sup">Â®</span>Â CREAM</span></p>
<p>(estradiol vaginal cream, USP, 0.01%)<span class="Bold">Â </span></p>
<p><span class="Bold">RxÂ only</span></p>
<p>Each gram contains</p>
<p>0.1 mg estradiol</p>
<p>in a nonliquefying base</p>
<p><span class="Bold">NETÂ WTÂ 1Â½Â OZÂ (42.5Â G)</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESTRACEÂ 		
					</strong><br><span class="contentTableReg">estradiol cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-3754</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">0.1Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CAPRYLIC/CAPRIC MONO/DIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TERT-BUTYLHYDROQUINONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CERESIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-3754-14</td>
<td class="formItem">36  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">42.5 g in 1 TUBE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-3754-95</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">12 g in 1 TUBE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA086069</td>
<td class="formItem">07/01/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott (US), LLC
							(957203177)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Organon API Inc.</td>
<td class="formItem"></td>
<td class="formItem">402157499</td>
<td class="formItem">API MANUFACTURE(0430-3754)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bayer Pharma AG</td>
<td class="formItem"></td>
<td class="formItem">323033480</td>
<td class="formItem">API MANUFACTURE(0430-3754)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Contract Pharmaceuticals Limited Canada</td>
<td class="formItem"></td>
<td class="formItem">246770700</td>
<td class="formItem">ANALYSIS(0430-3754)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cd3b5d4b-6a3c-4b13-a0b1-5ac63e0d8cb4</div>
<div>Set id: dfc41fcd-c5ba-4b25-b647-cf04d3988b3e</div>
<div>Version: 6</div>
<div>Effective Time: 20130930</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott (US), LLC</div></p>
</body></html>
